Literature DB >> 26053051

Receptor Activator of NF-κB Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages.

Taku Fujimura1, Yumi Kambayashi2, Sadanori Furudate2, Masayuki Asano2, Aya Kakizaki2, Setsuya Aiba2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26053051     DOI： 10.1038/jid.2015.209

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  12 in total

1.  The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages.

Authors:  Yumi Kambayashi; Taku Fujimura; Sadanori Furudate; Masayuki Asano; Aya Kakizaki; Setsuya Aiba
Journal:  J Invest Dermatol       Date:  2015-05-27       Impact factor: 8.551

Review 2.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

3.  Comparison of Foxp3+ regulatory T cells and CD163+ macrophages in invasive and non-invasive extramammary Paget's disease.

Authors:  Taku Fujimura; Yumi Kambayashi; Takanori Hidaka; Akira Hashimoto; Takahiro Haga; Setsuya Aiba
Journal:  Acta Derm Venereol       Date:  2012-11       Impact factor: 4.437

4.  Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells.

Authors:  Karin Loser; Annette Mehling; Stefanie Loeser; Jenny Apelt; Annegret Kuhn; Stephan Grabbe; Thomas Schwarz; Josef M Penninger; Stefan Beissert
Journal:  Nat Med       Date:  2006-12-03       Impact factor: 53.440

Review 5.  Alternative activation of macrophages: mechanism and functions.

Authors:  Siamon Gordon; Fernando O Martinez
Journal:  Immunity       Date:  2010-05-28       Impact factor: 31.745

6.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

Review 8.  Targeting RANKL in breast cancer: bone metastasis and beyond.

Authors:  Hamdy Azim; Hatem A Azim
Journal:  Expert Rev Anticancer Ther       Date:  2013-02       Impact factor: 4.512

9.  TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Authors:  B R Wong; R Josien; S Y Lee; B Sauter; H L Li; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  Potential use of bisphosphonates in invasive extramammary Paget's disease: an immunohistochemical Investigation.

Authors:  Taku Fujimura; Sadanori Furudate; Yumi Kambayashi; Setsuya Aiba
Journal:  Clin Dev Immunol       Date:  2013-03-31
View more
  21 in total

Review 1.  Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.

Authors:  Alessandro Del Conte; Elisa De Carlo; Elisa Bertoli; Brigida Stanzione; Alberto Revelant; Manuela Bertola; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

Review 2.  RANKL biology.

Authors:  Noriko Takegahara; Hyunsoo Kim; Yongwon Choi
Journal:  Bone       Date:  2022-02-16       Impact factor: 4.626

3.  RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

Authors:  Hong Wang; Reading Ashton; Jonathan A Hensel; Joo Hyoung Lee; Vinayak Khattar; Yong Wang; Jessy S Deshane; Selvarangan Ponnazhagan
Journal:  Mol Cancer Ther       Date:  2020-11-16       Impact factor: 6.261

Review 4.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

Review 5.  RANK-RANKL signalling in cancer.

Authors:  Nathalie Renema; Benjamin Navet; Marie-Françoise Heymann; Frédéric Lezot; Dominique Heymann
Journal:  Biosci Rep       Date:  2016-08-05       Impact factor: 3.840

6.  Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab.

Authors:  Sadanori Furudate; Taku Fujimura; Akira Tsukada; Yota Sato; Takanori Hidaka; Kayo Tanita; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2017-01-16

7.  Merkel Cell Carcinoma with Spontaneous Regression: A Case Report and Immunohistochemical Study.

Authors:  Hitoshi Terui; Taku Fujimura; Aya Kakizaki; Sadanori Furudate; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2016-02-24

8.  Periostin in the Cancer Stroma of Mycosis Fungoides Palmaris et Plantaris: A Case Report and Immunohistochemical Study.

Authors:  Kayo Tanita; Taku Fujimura; Aya Kakizaki; Sadanori Furudate; Masato Mizuashi; Akiko Watabe; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2016-02-06

9.  RANKL-Expressing Ectopic Extramammary Paget's Disease on the Lower Abdomen.

Authors:  Akiko Hagiwara-Takita; Taku Fujimura; Aya Kakizaki; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2016-06-06

Review 10.  Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.

Authors:  Taku Fujimura; Yumi Kambayashi; Yasuhiro Fujisawa; Takanori Hidaka; Setsuya Aiba
Journal:  Front Oncol       Date:  2018-01-23       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.